RxDoctor Payments Data

Mario Martinez, MD

Infectious Disease · Waco, TXNPI 1811425820

Payments from drug & device makers

$1,793in general payments, 2019–2025

Across 55 payments — averaging $32.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$513
  • Astellas Pharma US Inc$326
  • Gilead$269
  • Paratek Pharmaceuticals, Inc.$172
  • Pfizer$127
  • Melinta Therapeutics, LLC$109
  • plus $277 from 4 others

What the payments were for

  • Food & beverage$1,51985%
  • Education$27415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,793 in reported general payments places this provider in the 65th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$54,070
Medicare patients
160
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala123$528,703
IsentressRaltegravir Potassium52$100,131
CresembaIsavuconazonium Sulfate18$94,611
OdefseyEmtricitab/Rilpiviri/Tenof Ala26$92,693
JulucaDolutegravir/Rilpivirine22$82,187
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$64,454
TriumeqAbacavir/Dolutegravir/Lamivudi16$61,519
DovatoDolutegravir Sodium/Lamivudine12$35,907
Maraviroc25$32,013
Darunavir25$26,426
AptivusTipranavir12$24,716
Etravirine27$24,085
DescovyEmtricitabine/Tenofov Alafenam11$23,839
VemlidyTenofovir Alafenamide11$15,600
Lopinavir-RitonavirLopinavir/Ritonavir13$9,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Vemlidy$269$632,596160 claims
Viiv Healthcare CompanyJuluca, Triumeq, Dovato$513$179,61350 claims
MerckIsentress$29$100,13152 claims
Astellas Pharma US IncCresemba$326$94,61118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →